Overweight clinical trials

Explore recruiting overweight clinical trials.

Recruiting overweight studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Overweight trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)

Greece, Poland, Spain, Bulgaria, Italy, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)

Denmark, Poland, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)

Italy, Croatia, Hungary, Slovakia, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)

Poland, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)

Germany, Croatia, Portugal, Hungary, Bulgaria, Romania +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)

Italy, Greece, Spain, Bulgaria, Denmark, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Overweight trials by city

Overweight in Toronto Overweight in Vancouver Overweight in Montreal Overweight in Calgary Overweight in Edmonton Overweight in Ottawa Overweight in Winnipeg Overweight in Quebec City Overweight in Hamilton Overweight in Kitchener Overweight in London Overweight in Halifax Overweight in New York Overweight in Los Angeles Overweight in Chicago Overweight in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease